dc.contributor.author | Pigeon, Pascal | |
dc.contributor.author | Görmen, Meral | |
dc.contributor.author | Kowalski, Konrad | |
dc.contributor.author | Müller-Bunz, Helge | |
dc.contributor.author | McGlinchey, Michael J. | |
dc.contributor.author | Top, Siden | |
dc.contributor.author | Jaouen, Gérard | |
dc.date.accessioned | 2016-03-24T13:13:06Z | |
dc.date.available | 2016-03-24T13:13:06Z | |
dc.date.issued | 2014 | |
dc.identifier.issn | 1420-3049 | |
dc.identifier.uri | http://hdl.handle.net/11089/17534 | |
dc.description.abstract | In the course of the preparation of a series of ferrocenyl derivatives of diethylstilbestrol (DES), in which one of the 4-hydroxyphenyl moieties was replaced by a ferrocenyl group, the McMurry reaction of chloropropionylferrocene with a number of mono-aryl ketones unexpectedly yielded the hydroxylated ferrocenyl DES derivatives, 5a–c, in poor yields (10%–16%). These compounds showed high activity on the hormone-independent breast cancer cell line MDA-MB-231 with IC50 values ranging from 0.14 to 0.36 µM. Surprisingly, non-hydroxylated ferrocenyl DES, 4, showed only an IC50 value of 1.14 µM, illustrating the importance of the hydroxyethyl function in this promising new series. For comparison, McMurry reactions of the shorter chain analogue chloroacetylferrocene were carried out to see the difference in behaviour with mono-aryl ketones versus a diaryl ketone. The effect of changing the length of the alkyl chain adjacent to the phenolic substituent of the hydroxylated ferrocenyl DES was studied, a mechanistic rationale to account for the unexpected products is proposed, and the antiproliferative activities of all of these compounds on MDA-MB-231 cells lines were measured and compared. X-ray crystal structures of cross-coupled products and of pinacol-pinacolone rearrangements are reported. | pl_PL |
dc.description.sponsorship | The authors wish to thank P. Herson and J. Vaissermann for three crystal structure determinations
and T. Cresteil for IC50 determinations. We thank Anh N’Guyen for full discussions. K.K.’s stay in
Paris was supported through an European Community Marie Curie Fellowship (HMPT-CT-2000-
00186). We thank the Agence Nationale de la Recherche for financial support (ANR 2010 BLAN 7061
blanc “Mecaferrol”) and the Ministère des Affaires Etrangères for a doctoral fellowship (M.G.). | pl_PL |
dc.language.iso | en | pl_PL |
dc.publisher | MDPI | pl_PL |
dc.relation.ispartofseries | Molecules;7 | |
dc.rights | Uznanie autorstwa 3.0 Polska | * |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/pl/ | * |
dc.subject | DES | pl_PL |
dc.subject | ferrocene | pl_PL |
dc.subject | pinacol rearrangement | pl_PL |
dc.subject | McMurry reaction | pl_PL |
dc.subject | antiproliferative activity | pl_PL |
dc.subject | MDA-MB-231 | pl_PL |
dc.title | Atypical McMurry Cross-Coupling Reactions Leading to a New Series of Potent Antiproliferative Compounds Bearing the Key [Ferrocenyl-Ene-Phenol] Motif | pl_PL |
dc.type | Article | pl_PL |
dc.page.number | 10350-10369 | pl_PL |
dc.contributor.authorAffiliation | Chimie ParisTech, 11 rue Pierre et Marie Curie | pl_PL |
dc.contributor.authorAffiliation | Sorbonne Universités | pl_PL |
dc.contributor.authorAffiliation | University of Łódź, Faculty of Chemistry | pl_PL |
dc.contributor.authorAffiliation | University College Dublin | pl_PL |
dc.references | Jaouen, G.; Top, S. The Ferrocifen family as Potent and Selective Antitumor Compounds: Mechanisms of Action. In Advances in Organometallic Chemistry and Catalysis; Pombeiro, A.J.L., Ed.; Wiley: Hoboken, NJ, USA, 2014; pp. 563–580. | pl_PL |
dc.references | Barry, N.P.E.; Sadler, P.J. Exploration of the medical periodic table: Towards new targets. Chem. Commun. 2013, 49, 5106–5131. | pl_PL |
dc.references | Bertrand, B.; Casini, A. A golden future in medicinal inorganic chemistry: The promise of anticancer gold organometallic compounds. Dalton Trans. 2014, 43, 4209–4219. | pl_PL |
dc.references | Braga, S.S.; Silva, A.M.S. A new age for iron: Antitumoral ferrocenes. Organometallics 2013, 32, 5626–5639. | pl_PL |
dc.references | Hillard, E.A.; Jaouen, G. Bioorganometallics: Future trends in drug discovery, analytical chemistry and catalysis. Organometallics 2011, 30, 20–27. | pl_PL |
dc.references | Hillard, E.A.; Vessières, A.; Jaouen, G. Topics in organometallic chemistry. In In Medicinal Organometallic Chemistry; Jaouen, G., Metzler-Nolte, N, Eds.; Springer-Verlag: Heidelberg, Germany, 2010; volume 32, p. 81. | pl_PL |
dc.references | Ornelas, C. Application of ferrocene and its derivatives in cancer research. New J. Chem. 2011, 35, 1973–1985. | pl_PL |
dc.references | Top, S.; Vessières, A.; Leclercq, G.; Quivy, J.; Tang, J.; Vaissermann, J.; Huché, M.; Jaouen, G. Synthesis, biochemical properties and molecular modeling studies of organometallic specific estrogen receptor modulators (SERMs), the ferrocifens and hydroxyferrocifens: Evidence for an antiproliferative effect of hydroxyferrocifens on both hormone-dependent and hormone-independent breast cancer cell lines. Chem. Eur. J. 2003, 9, 5223–5236. | pl_PL |
dc.references | Top, S.; Tang, J.; Vessières, A.; Carrez, D.; Provot, C.; Jaouen, G. Ferrocenyl hydroxytamoxifen: A prototype for a new range of estradiol receptor site-directed cytotoxics. Chem. Commun. 1996, 8, 955–956. | pl_PL |
dc.references | Vessières, A.; Top, S.; Pigeon, P.; Hillard, E.A.; Boubeker, L.; Spera, D.; Jaouen, G. Modification of the estrogenic properties of diphenols by the incorporation of ferrocene. Generation of anti-proliferative effects in vivo. J. Med. Chem. 2005, 48, 3937–3940. | pl_PL |
dc.references | O’Regan, R.M.; Cisneros, A.; England, G.M.; MacGregor, J.I.; Muenzner, H.D.; Assikis, V.J.; Bilimoria, M.M.; Piette, M.; Dragan, Y.P.; Pitot, H.C.; et al. Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth. J. Natl. Cancer Inst. 1998, 90, 1552–1558. | pl_PL |
dc.references | Valavaara, R.; Pyrhönen, S.; Heikkinen, M.; Rissanen, P.; Blanco, G.; Thölix, E.; Nordman, E.; Taskinen, P.; Holsti, L.; Hajba, A. Toremifene, a new antiestrogenic compound, for treatment of advanced breast cancer. Phase II study. J. Cancer Clin. Oncol. 1988, 24, 785–790. | pl_PL |
dc.references | Gundersen, S. Toremifene, a new antiestrogenic compound in the treatment of metastatic mammary cancer. A phase II study. J. Steroid Biochem. 1990, 36, 233–234. | pl_PL |
dc.references | Modig, H.; Borgström, S.; Nilsson, I.; Westman, G. Phase II clinical study of toremifene in patients with metastatic breast cancer. Preliminary communication. J. Steroid Biochem. 1990, 36, 235–236. | pl_PL |
dc.references | Milla-Santos, A.; Milla, L.; Rallo, L.; Solano, V. Phase III randomized trial of toremifene vs. tamoxifen in hormonodependant advanced breast cancer. Breast Cancer Res. Treat. 2001, 65, 119–124. | pl_PL |
dc.references | Baur, J.A.; Pearson, K.J.; Price, N.L.; Jamieson, H.A.; Lerin, C.; Kalra, A.; Prabhu, V.V.; Allard, J.S.; Lopez-Lluch, G.; Lewis, K.; et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006, 444, 337–342. | pl_PL |
dc.references | Raghow, S.; Hooshdaran, M.Z.; Katiyar, S.; Steiner, M.S. Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model. Cancer Res. 2002, 62, 1370–1376. | pl_PL |
dc.references | Smith, M.R.; Malkowicz, S.B.; Chu, F.; Forrest, J.; Price, D.; Sieber, P.; Barnette, K.G.; Rodriguez, D.; Steiner, M.S. Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: Interim analysis of a multicenter phase 3 clinical study. J. Urol. 2008, 179, 152–155. | pl_PL |
dc.references | Buriez, O.; Heldt, J.M.; Labbé, E.; Vessières, A.; Jaouen, G.; Amatore, C. Reactivity and antiproliferative activity of ferrocenyl-tamoxifen adducts with cyclodextrins against hormone-independent breast-cancer cell lines. Chem.-Eur. J. 2008, 14, 8195–8203. | pl_PL |
dc.references | Van Lipzig, M.M.H.; ter Laak, A.M.; Jongejan, A.; Vermeulen, N.P.E.; Wamelink, M.; Geerke, D.; Meerman, J.H.N. Prediction of ligand binding affinity and orientation of xenoestrogens to the estrogen receptor by molecular dynamics simulations and the linear interaction energy method. J. Med. Chem. 2004, 47, 1018–1030. | pl_PL |
dc.references | Giusti, R.M.; Iwamoto, K.; Hatch, E.E. Diethylstilbestrol revisited: A review of the long-term health effects. Ann. Intern. Med. 1995, 122, 778–788. | pl_PL |
dc.references | Schrager, S.; Potter, B.E. Diethylstilbestrol exposure. Am. Fam. Physician 2004, 69, 2395–2400. | pl_PL |
dc.references | Jaouen, G.; Top, S.; Vessières, A.; Sayer, B.G.; Frampton, C.S.; McGlinchey, M. Molecular recognition using bioorganometallic probes: NMR, X-ray crystallographic, and molecular modeling study of the conformations of chromium tricarbonyl derivatives of hexestrol and their relevance to estradiol-receptor binding. J. Organomet. 1992, 11, 4061–4068. | pl_PL |
dc.references | Tondu, S.; Top, S.; Vessières, A.; Jaouen, G. The use of tricarbonyl chromium hexestrol derivatives in the detection of oestradiol receptor sites. J. Chem. Soc. Chem. Commun. 1985, 326–328. | pl_PL |
dc.references | Gruselle, M.; Malezieux, B.; Sokolov, V.I.; Troitskaya, L.L. Enantioselective synthesis of ferrocene analogs of hexestrol and estradiol; recognition towards estradiol receptors. Inorganica. Chim. Acta 1994, 222, 51–61. | pl_PL |
dc.references | Hillard, E.A.; Vessières, A.; Top, S.; Pigeon, P.; Kowalski, K.; Huché, M.; Jaouen, G. Organometallic diphenols: The importance of the organometallic moiety on the expression of a cytotoxic effect on breast cancer cells. J. Organomet. Chem. 2007, 692, 1315–1326. | pl_PL |
dc.references | Elecko, P.; Foltinova, P.; Salisova, M.; Solcaniova, E.; Toma, S. Synthesis, proton magnetic resonance spectra, and biological activity of haloacylferrocenes. Chemicke. Zvesti. 1974, 28, 94–99. | pl_PL |
dc.references | Ephritikhine, M. A new look at the McMurry reaction. Chem. Commun. 1998, 23, 2549–2554. | pl_PL |
dc.references | Görmen, M.; Pigeon, P.; Hillard, E.A.; Vessières, A.; Huché, M.; Richard, M.-A.; McGlinchey, M.J.; Top, S.; Jaouen, G. Synthesis and antiproliferative effects of [3]ferrocenophane transposition products and pinacols obtained from McMurry cross-coupling reactions. Organometallics 2012, 31, 5856–5866. | pl_PL |
dc.references | Tan, Y.L.K.; Pigeon, P.; Hillard, E.A.; Top, S.; Plamont, M.-A.; Vessières, A.; McGlinchey, M.J.; Müller-Bunz, H.; Jaouen, G. Synthesis, oxidation chemistry and cytotoxicity studies on ferrocene derivatives of diethylstilbestrol. Dalton Trans. 2009, 10871–10881. | pl_PL |
dc.references | Schlögl, K.; Egger, H. Syntheses and reactions of ferrocenylacetylenes. Monatsh. Chem. 1963, 94, 376–392. | pl_PL |
dc.references | Ortin, Y.; Grealis, J.; Scully, C.; Müller-Bunz, H.; Manning, A.R.; McGlinchey, M.J. McMurry reactions of (η5-acetylcyclopentadienyl)cobalt(η4-tetraphenylcyclo-butadiene) with benzo-phenone: Ketone couplings and a pinacol-pinacolone rearrangement. J. Organomet. Chem. 2004, 689, 4683–4690. | pl_PL |
dc.references | Baddeley, G. Modern aspects of the Friedel-Crafts reaction. Quart. Rev. 1954, 8, 355–379. | pl_PL |
dc.references | Hillard, E.A.; Pigeon, P.; Vessières, A.; Amatore, C.; Jaouen, G. The influence of phenolic hydroxy substitution on the electron transfer and anti-cancer properties of compounds based on the 2-ferrocenyl-1-phenyl-but-1-ene motif. Dalton Trans. 2007, 43, 5073–5081. | pl_PL |
dc.references | Hillard, E.A.; Vessières, A.; le Bideau, F.; Plazuk, D.; Spera, D.; Huché, M.; Jaouen, G. A series of unconjugated ferrocenyl phenols: Prospects as anticancer agents. Chem. Med. Chem. 2006, 1, 551–559. | pl_PL |
dc.references | Heilmann, J.B.; Hillard, E.A.; Plamont, M.-A.; Pigeon, P.; Bolte, M.; Jaouen, G.; Vessières, A. Ferrocenyl compounds possessing protected phenol and thiophenol groups: Synthesis, X-ray structure, and in vitro biological effects against breast cancer. J. Organomet. Chem. 2008, 693, 1716–1722. | pl_PL |
dc.references | Görmen, M.; Pigeon, P.; Top, S.; Vessières, A.; Plamont, M.-A.; Hillard, E.A.; Jaouen, G. Facile synthesis and strong antiproliferative activity of disubstituted diphenylmethylidenyl-[3]ferrocenophanes on breast and prostate cancer cell lines. Med. Chem. Commun. 2010, 1, 149–151. | pl_PL |
dc.references | Görmen, M.; Plażuk, D.; Pigeon, P.; Hillard, E.A.; Plamont, M.-A.; Top, S.; Vessières, A.; Jaouen, G. Comparative toxicity of [3]ferrocenophane and ferrocene moieties on breast cancer cells. Tetrahedron Lett. 2010, 51, 118–120. | pl_PL |
dc.references | X-ray data for 14: The unit cell is orthogonal with a = 9.8552(7) Å, b = 9.7478(8) Å, c = 18.523(2) Å, α = β = γ = 90°, V = 1729.5(2) Å3, and the space group is Pnma (#62). | pl_PL |
dc.identifier.doi | 10.3390/molecules190710350 | |
dc.relation.volume | 19 | pl_PL |